tiprankstipranks
Neogen (DE:NG2)
NASDAQ:NG2
Germany Market

Neogen (NG2) Blogger Opinions & Sentiment

2 Followers

Blogger Sentiment

Bullish: 100.00%
Sector Average
Bullish
DE:NG2 Blogger sentiment is based on 4 Blogger Opinions. The Blogger sentiment is more Bullish than other stocks in the Healthcare sector.

Blogger Article Distribution

ArticleDistribution
100% SeekingAlpha
The distribution of articles among the main online Financial Blogging platforms.

Top Blogger Bearish Predictions

Not enough top blogger opinions at this time
Please return soon. This page is being updated.
Recent negative articles by top bloggers.

Top Blogger Bullish Predictions

Neogen: Starting 2026 With A Bang
SeekingAlpha
The Bottom Fishing Club - Neogen: Combine Business Turnaround With Defensive Trading History
SeekingAlpha
Neogen Q4 Preview: Focusing On Food And Animal Safety, Initiate At Buy
SeekingAlpha
Recent positive articles by top bloggers.

Financial Blogger Predictions​​

Blogger Performance
Any
Any
Blogger Sentiment
Any
Any

FAQ

What do Seeking Alpha bloggers think of DE:NG2?
Seeking Alpha’s The Value Investor has a Bullish Sentiment.
    What do Motley Fool contributors think of DE:NG2?
    Currently there's no blogger sentiment for DE:NG2.
    What Is DE:NG2’s Blogger Sentiment?
    DE:NG2’s Blogger Sentiment is Bullish.
      What was the most recent blogger prediction for DE:NG2?
      The most recent blogger prediction for DE:NG2 was made by The Value Investor, who was Bullish on the stock.
        How can I follow the stock ratings of top Top Financial Bloggers?
        Head over to our Expert Center to see a list of the Top 100 Financial Bloggers and follow the financial bloggers of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Stocks with the Highest Top Blogger Ratings in the Healthcare sector
          SPHRFStarpharma Holdings Limited
          PRRUFImmutep Ltd
          NURPFNeuren Pharmaceuticals Limited
          CLVLFClinuvel Pharmaceuticals